Browse by UCL people
Group by: Type | Date
Jump to: Article
Number of items: 8.
Article
Coltart, CEM;
Hoppe, A;
Parker, M;
Dawson, L;
Amon, JJ;
Simwinga, M;
Geller, G;
... Ethics in HIV Phylogenetics Working Group; + view all
(2018)
Ethical considerations in global HIV phylogenetic research.
The Lancet HIV
, 5
(11)
e656-e666.
10.1016/S2352-3018(18)30134-6.
|
|
Hakim, JG;
Thompson, J;
Kityo, C;
Hoppe, A;
Kambugu, A;
van Oosterhout, JJ;
Lugemwa, A;
... Europe Africa Research Network for Evaluation of Second-line The; + view all
(2017)
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
Lancet Infectious Diseases
, 18
(1)
pp. 47-57.
10.1016/S1473-3099(17)30630-8.
|
 |
|
Hoppe, A;
Guilano, M;
Lugemwa, A;
Thompson, J;
Floridia, M;
Walker, AS;
Senoga, I;
... Paton, NI; + view all
(2017)
HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.
Antiviral Therapy
10.3851/IMP3200.
(In press).
|
|
Kambugu, A;
Thompson, J;
Hakim, J;
Tumukunde, D;
van Oosterhout, JJ;
Mwebaze, R;
Hoppe, A;
... EARNEST Trial Team; + view all
(2016)
Neurocognitive Function at the First-Line Failure and on the Second-Line Antiretroviral Therapy in Africa: Analyses From the EARNEST Trial.
JAIDS Journal of Acquired Immune Deficiency Syndromes
, 71
(5)
pp. 506-513.
10.1097/QAI.0000000000000898.
|
|
Kityo, C;
Thompson, J;
Nankya, I;
Hoppe, A;
Ndashimye, E;
Warambwa, C;
Mambule, I;
... Paton, N; + view all
(2017)
HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in sub-Saharan Africa.
JAIDS: Journal of Acquired Immune Deficiency Syndromes
, 75
(2)
e45-e54.
10.1097/QAI.0000000000001285.
|
|
Lambert-Niclot, S;
George, EC;
Pozniak, A;
White, E;
Schwimmer, C;
Jessen, H;
Johnson, M;
... NEAT 001/ANRS 143 Study Group, .; + view all
(2016)
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Journal of Antimicrobial Chemotherapy
, 71
(4)
pp. 1056-1062.
10.1093/jac/dkv427.
|
|
Paton, NI;
Kityo, C;
Thompson, J;
Nankya, I;
Bagenda, L;
Hoppe, A;
Hakim, JG;
... Walker, AS; + view all
(2017)
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
The Lancet HIV
, 4
(8)
e341-e348.
10.1016/S2352-3018(17)30065-6.
|
|
|
Yebra, G;
Hodcroft, EB;
Ragonnet-Cronin, ML;
Kozlakidis, Z;
Pillay, D;
Nastouli, E;
Hayward, A;
(2016)
Using nearly full-genome HIV sequence data improves phylogeny reconstruction in a simulated epidemic.
Scientific Reports
, 6
, Article 39489. 10.1038/srep39489.
|
|
